![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Eisai to Adopt Tiered Royalty Model Instead of Shared Profits/Losses With Biogen for Aduhelm
Eisai to Adopt Tiered Royalty Model Instead of Shared Profits/Losses With Biogen for Aduhelm
Eisai has given up its rights to share profits and losses with Biogen on the controversial Alzheimer’s drug Aduhelm (aducanumab-avwa), which the companies developed together. Instead, Eisai will get tiered royalties on net sales beginning Jan. 1, 2023.
Eisai will receive royalties starting at 2 percent and reaching 8 percent when annual sales of Aduhelm exceed $1 billion. And Biogen will now have sole commercialization rights regarding Aduhelm.
The FDA approved Aduhelm last summer even though one of its phase 3 trials didn't show a patient benefit and a panel of FDA advisers voted against the drug. Late last year, Biogen announced that it was dropping the yearly price of Aduhelm by half to $28,200.
Upcoming Events
-
21Oct